JP2006523711A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523711A5
JP2006523711A5 JP2006510118A JP2006510118A JP2006523711A5 JP 2006523711 A5 JP2006523711 A5 JP 2006523711A5 JP 2006510118 A JP2006510118 A JP 2006510118A JP 2006510118 A JP2006510118 A JP 2006510118A JP 2006523711 A5 JP2006523711 A5 JP 2006523711A5
Authority
JP
Japan
Prior art keywords
composition
seq
composition according
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006510118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523711A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/011767 external-priority patent/WO2004093894A2/en
Publication of JP2006523711A publication Critical patent/JP2006523711A/ja
Publication of JP2006523711A5 publication Critical patent/JP2006523711A5/ja
Withdrawn legal-status Critical Current

Links

JP2006510118A 2003-04-17 2004-04-16 免疫調節因子としてのb7−h3の使用 Withdrawn JP2006523711A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46334203P 2003-04-17 2003-04-17
PCT/US2004/011767 WO2004093894A2 (en) 2003-04-17 2004-04-16 Use of b7-h3 as an immunoregulatory agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007095108A Division JP2007191489A (ja) 2003-04-17 2007-03-30 免疫調節因子としてのb7−h3の使用

Publications (2)

Publication Number Publication Date
JP2006523711A JP2006523711A (ja) 2006-10-19
JP2006523711A5 true JP2006523711A5 (https=) 2007-05-24

Family

ID=33310770

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006510118A Withdrawn JP2006523711A (ja) 2003-04-17 2004-04-16 免疫調節因子としてのb7−h3の使用
JP2007095108A Withdrawn JP2007191489A (ja) 2003-04-17 2007-03-30 免疫調節因子としてのb7−h3の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007095108A Withdrawn JP2007191489A (ja) 2003-04-17 2007-03-30 免疫調節因子としてのb7−h3の使用

Country Status (14)

Country Link
US (1) US20050002935A1 (https=)
EP (1) EP1620119A2 (https=)
JP (2) JP2006523711A (https=)
KR (1) KR20060017496A (https=)
CN (1) CN1809370A (https=)
AU (1) AU2004231748A1 (https=)
BR (1) BRPI0409476A (https=)
CA (1) CA2521847A1 (https=)
CO (1) CO5700783A2 (https=)
MX (1) MXPA05011050A (https=)
NO (1) NO20054790L (https=)
RU (1) RU2005135739A (https=)
WO (1) WO2004093894A2 (https=)
ZA (1) ZA200508367B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
CA2571420A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012147713A1 (ja) * 2011-04-25 2012-11-01 第一三共株式会社 抗b7-h3抗体
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MX2019011117A (es) * 2017-03-31 2019-11-05 Jiangsu Hengrui Medicine Co Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CN109097366A (zh) * 2017-06-21 2018-12-28 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用
US12312406B2 (en) 2018-11-09 2025-05-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
CA3124721A1 (en) * 2018-12-24 2020-07-02 Xiaoyi Zhou Recombinant human 21g-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof
CN118878681A (zh) * 2019-07-18 2024-11-01 泰州复旦张江药业有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技(成都)有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法
EP4257154A4 (en) 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
CN119212733A (zh) 2022-05-18 2024-12-27 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024148521A1 (zh) * 2023-01-10 2024-07-18 周田弘 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6965018B2 (en) * 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US6891030B2 (en) * 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
EP1423402A4 (en) * 2001-08-02 2006-07-05 Lilly Co Eli NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2006523711A5 (https=)
Kim et al. Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy
JP2022137020A (ja) 抗cd70キメラ抗原受容体
AU2025237926A1 (en) Nanoparticle compositions for sustained therapy
JP2023025108A (ja) Hla-cw8拘束性の変異krasを認識するt細胞受容体
JP7250790B2 (ja) Il-2ムテインおよびその使用
TW202122416A (zh) 多鏈嵌合多肽及其用途
Wiesel et al. Virus‐specific CD8 T cells: activation, differentiation and memory formation
JP2016502512A5 (https=)
RU2005135739A (ru) Способ регулирования активации лимфоцита (варианты)
JP2006507231A5 (https=)
JP2015508757A5 (https=)
JP2018029594A5 (https=)
EP3714042A1 (en) Use and production of engineered immune cells
BR112019009477A2 (pt) moléculas de classe ii de pmhc recombinantes
WO2016154621A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
JP2010273685A5 (https=)
JP2013505734A5 (https=)
JP2013513377A5 (https=)
US20240010976A1 (en) Methods and compositions for stimulating gamma delta t cells
JP2019513394A5 (https=)
JP2011520989A5 (https=)
JP2019530441A5 (https=)
JP2011523849A5 (https=)
KR20210144737A (ko) T 세포 수용체 및 이의 사용 방법